PubMed Health⌕ Search

Biomedical subjects

James Lyons-Weiler

Publications and source records attributed to James Lyons-Weiler.

5 recordsLinked to original sources

Tests for finding complex patterns of differential expression in cancers: towards individualized medicine.

BACKGROUND: Microarray studies in cancer compare expression levels between two or more sample groups on thousands of genes. Data analysis follows a population-level approach (e.g., comparison of sample means) to identify differentially expressed genes. This leads to the discovery of 'population-level' markers, i.e., genes with the expression patterns A > B and B > A. We introduce the PPST test that identifies genes where a significantly large subset of cases exhibit expression values beyond upper and lower thresholds observed in the control samples. RESULTS: Interestingly, the test identifies A > B and B < A pattern genes that are missed by population-level approaches, such as the t-test, and many genes that exhibit both significant overexpression and significant underexpression in statistically significantly large subsets of cancer patients (ABA pattern genes). These patterns tend to show distributions that are unique to individual genes, and are aptly visualized in a 'gene expression pattern grid'. The low degree of among-gene correlations in these genes suggests unique underlying genomic pathologies and high degree of unique tumor-specific differential expression. We compare the PPST and the ABA test to the parametric and non-parametric t-test by analyzing two independently published data sets from studies of progression in astrocytoma. CONCLUSIONS: The PPST test resulted findings similar to the nonparametric t-test with higher self-consistency. These tests and the gene expression pattern grid may be useful for the identification of therapeutic targets and diagnostic or prognostic markers that are present only in subsets of cancer patients, and provide a more complete portrait of differential expression in cancer.

Delivery of Health Care↗

A classification-based machine learning approach for the analysis of genome-wide expression data.

Three important areas of data analysis for global gene expression analysis are class discovery, class prediction, and finding dysregulated genes (biomarkers). The clinical application of microarray data will require marker genes whose expression patterns are sufficiently well understood to allow accurate predictions on disease subclass membership. Commonly used methods of analysis include hierarchical clustering algorithms, t-, F-, and Z-tests, and machine learning approaches. We describe an approach called the maximum difference subset (MDSS) algorithm that combines classification algorithms, classical statistics, and elements of machine learning and provides a coherent framework. By integrating prediction accuracy, the MDSS algorithm learns the critical threshold of statistical significance (the alpha or P-value), eliminating the arbitrariness of setting a threshold of statistical significance and minimizing the effect of the normality assumptions. To reduce the false positive rate and to increase external validity of the predictive gene set, a jackknife step is used. This step identifies and removes genes in the initial MDSS with low combined predictive utility. The overall MDSS provides a prediction that is less dependent on an arbitrary study design (sample inclusion or exclusion) and should thus have high external validity. We demonstrate that this approach, unlike other published methods, identifies biomarkers capable of predicting the outcome of anthracycline-cytarabine chemotherapy in cases of acute myeloid leukemia. By incorporating two criteria-statistical significance and predictive utility-the approach learns the significance level relevant for a given data set. The MDSS approach can be used with any test and classifier operator pair.

Acute Disease↗

Overcoming confounded controls in the analysis of gene expression data from microarray experiments.

A potential limitation of data from microarray experiments exists when improper control samples are used. In cancer research, comparisons of tumour expression profiles to those from normal samples is challenging due to tissue heterogeneity (mixed cell populations). A specific example exists in a published colon cancer dataset, in which tissue heterogeneity was reported among the normal samples. In this paper, we show how to overcome or avoid the problem of using normal samples that do not derive from the same tissue of origin as the tumour. We advocate an exploratory unsupervised bootstrap analysis that can reveal unexpected and undesired, but strongly supported, clusters of samples that reflect tissue differences instead of tumour versus normal differences. All of the algorithms used in the analysis, including the maximum difference subset algorithm, unsupervised bootstrap analysis, pooled variance t-test for finding differentially expressed genes and the jackknife to reduce false positives, are incorporated into our online Gene Expression Data Analyzer ( http:// bioinformatics.upmc.edu/GE2/GEDA.html ).

Algorithms↗

Homocysteine, folate deprivation and Alzheimer neuropathology.

Increased levels of homocysteine (HC), arising in some situations via deficiencies in folate--an essential cofactor in metabolic regulation of HC--have long been known to contribute to cardiovascular disorders and stroke. More recently, clinical studies implicate increased HC and reduced folate with neurodegenerative conditions including Alzheimer's disease. It has remained unclear from clinical studies whether the neurotoxicity of increased HC and/or reduced folate is derived from direct detrimental effects on neurons themselves, or is instead derived indirectly following perturbation of nervous system vasculature. However, recent reports from several laboratories provide evidence that HC not only induces direct neurotoxicity, but also potentiates both amyloid-beta and glutamate neurotoxicity. These latter studies leave open the possibility that even mild elevations in HC may place neurons at risk for additional trauma. The potential contribution of folate deficiency and resultant increases in HC to neurodegeneration in AD, and therapeutic approaches to alleviate their impact, is discussed.

Alzheimer Disease↗